Bermuda-based biotechnology company Axovant Sciences has priced its $40 million underwritten public offering.
Axovant Sciences will issue 26.7 million of its common shares at a price of $1.50 per share. Jefferies and Guggenheim Securities are acting as joint book-runners for the offering.
In addition, Axovant has granted the underwriters a 30-day option to buy up to an extra 4 million of its common shares on the same terms and conditions.
The offering will be closed on March 18, 2019, subject to customary closing conditions.